<SEC-DOCUMENT>0000105770-16-000092.txt : 20160912
<SEC-HEADER>0000105770-16-000092.hdr.sgml : 20160912
<ACCEPTANCE-DATETIME>20160912164346
ACCESSION NUMBER:		0000105770-16-000092
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160912
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160912
DATE AS OF CHANGE:		20160912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			WEST PHARMACEUTICAL SERVICES INC
		CENTRAL INDEX KEY:			0000105770
		STANDARD INDUSTRIAL CLASSIFICATION:	FABRICATED RUBBER PRODUCTS, NEC [3060]
		IRS NUMBER:				231210010
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08036
		FILM NUMBER:		161881351

	BUSINESS ADDRESS:	
		STREET 1:		530 HERMAN O. WEST DRIVE
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341
		BUSINESS PHONE:		6105942900

	MAIL ADDRESS:	
		STREET 1:		530 HERMAN O. WEST DRIVE
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WEST CO INC
		DATE OF NAME CHANGE:	19990405
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sept122016form8k.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD12B11AA82A29D07A0FC1E9BEAD3DD4E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:4px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of Earliest Event Reported) &#8211; September 12, 2016 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="wst8klogosept122016.jpg" alt="wst8klogosept122016.jpg" style="height:101px;width:252px;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WEST PHARMACEUTICAL SERVICES, INC.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:27%;"></td><td style="width:4%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pennsylvania</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-8036</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23-1210010</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530 Herman O. West Drive, Exton, PA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19341-0645</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">610-594-2900</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or address, if changed since last report)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sE27D53DA8F626DE1BD891E9BEAF1667A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 12, 2016, West Pharmaceutical Services, Inc. (the "Company") announced that its Board of Directors (the "Board") had elected Paolo Pucci to fill the vacancy following the retirement of Anthony Welters.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pucci, 55, is Chief Executive Officer of ArQule, Inc., a biopharmaceutical company engaged in the research and development of targeted therapeutics. Prior to his joining ArQule in 2008, Mr. Pucci worked at Bayer A.G., where he served in a number of leadership capacities including Senior Vice President of the Global Specialty Medicine Business Unit and was a member of the Bayer Pharmaceuticals Global Management Committee.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pucci will be entitled </font><font style="font-family:inherit;font-size:10pt;color:#0f1011;">to the customary compensation arrangements for the Company&#8217;s non-employee directors, which consists of an $80,000 annual retainer and a restricted stock unit grant of $160,000, both prorated based on Mr. Pucci's period of service in 2016. In addition, he will be eligible to participate in the Company's Director Deferred Compensation Plan. The Company&#8217;s most recent proxy statement, filed with the Securities and Exchange Commission on March 23, 2016, describes these arrangements under the heading &#8220;Director Compensation.&#8221;  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pucci will enter into our standard form of indemnification agreement, the form of which was included as Exhibit&#160;10.1 to our Current Report on Form 8-K filed on January 6, 2009.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no arrangements or understandings between Mr. Pucci and any other person pursuant to which he was elected as a director, and there are and have been no transactions since the beginning of the Company&#8217;s last fiscal year, or currently proposed, between the Company and Mr Pucci. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01 Regulation FD Disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 12, 2016, the Company issued a press release announcing the appointment of Mr. Pucci to the Board and approval of a fourth quarter dividend of $0.13 per share, an 8.3% increase over the $0.12 per share declared for each of the four preceding quarters. The dividend will be paid on November 2, 2016, to shareholders of record as of October 19, 2016. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information included in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01&#160;Financial Statements and Exhibits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:12%;"></td><td style="width:79%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibits</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">West Pharmaceutical Services, Inc. Press Release, dated September 12, 2016.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s72049A5C10789F8A1AA21E9BEB23ECCE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:44%;"></td><td style="width:41%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WEST PHARMACEUTICAL SERVICES, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ William J. Federici</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William J. Federici</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 12, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s35742C5379EC1D933AC21E9BEB411D09"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">West Pharmaceutical Services, Inc. Press Release, dated September 12, 2016.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh991sept122016pressrelea.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5011111900ef4ec0948bd8dca65f138d"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><img src="exh991logosept122016.jpg" alt="exh991logosept122016.jpg" style="height:57px;width:337px;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:right;padding-left:54px;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:600px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:394px;"></td><td style="width:205px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Investor and Media Contact:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quintin Lai, Investor Relations</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">+1-610-594-3318                                  Quintin.Lai@westpharma.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">West Elects New Director and Announces Increase to Quarterly Dividend</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXTON, PA, September 12, 2016 -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that the Company&#8217;s Board of Directors elected Paolo Pucci to fill the vacancy following the retirement of Anthony Welters.  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mr. Pucci, 54, is Chief Executive Officer of ArQule, Inc., a biopharmaceutical company engaged in the research and development of targeted therapeutics. Prior to his joining ArQule in 2008, Mr. Pucci worked at Bayer A.G., where he served in a number of leadership capacities including Senior Vice President of the Global Specialty Medicine Business Unit and was a member of the Bayer Pharmaceuticals Global Management Committee.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We are pleased to enhance the experience base of our independent directors,&#8221; said Patrick J. Zenner, Chairman of the Board of Directors, West. &#8220;Paolo broadens the Board&#8217;s expertise in leading complex, growing, multi-national businesses. With over 25 years in the pharmaceutical industry, including 17 years at Bayer A.G. and Eli Lilly, Paolo brings insight into all aspects of drug commercialization on an international scale as well as R&amp;D trends for new therapeutic drugs for cancer and certain rare diseases, an important market for West&#8217;s portfolio of containment, administration and delivery technologies for injectable drugs.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additionally, the Board also approved a fourth-quarter 2016 dividend of $0.13 per share, an 8.3% increase over the $0.12 per share declared for each of the four preceding quarters. This is the twenty-fourth consecutive annual increase in the Company&#8217;s dividend. The fourth-quarter dividend will be paid on November 2, 2016, to shareholders of record as of October 19, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About West</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">West Pharmaceutical Services, Inc., is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2015 sales of $1.4 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exh991logosept122016.jpg
<TEXT>
begin 644 exh991logosept122016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M+;;-&)$ <R+D[2,C'%>9:C_P<N_L]Z=8S3G2/BE*(D+[(_#REWP/N@>=R3T
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MM^#,OB$Z#K7B_P 0WS-:Z%X?TFTFN+K5;K;NP?*1S'"H^9Y2N%& ,LRJ=?\
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MX?U+XZ>)6T[P5I^I^-]9N),O#HD+ZI.SGO(8MV"<=7(Z5^L?_!(K_@AYX@\
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M:5]KWZ>1V'QU\!W^O^-)=0\6>-(_#/@F",K:Q6MV8IW<*.JE<,Q)8DX8@
M9R.4^"?C2^UOX._$K2I]3N-7L-*LW:QGG9F=HV64 Y8D@,$5MI/&XBHO$&H?
MV3^U-K%YXL\-:UXD5,QZ);P6IGCQN7RBH)"E=N[G) 8DD=POP<TG4E\._&!K
MO2KVQN+VW=UMWA;ABUP2B':-^TG&5Z\>M8*%J%I._P +6UMUMU]6=[J<^.<Z
M::NZB=^9MVB[7Z)?RI'':_IMR_[*FAWRWC+8V^LW,$MEM^6>1@624MG@J$9<
M8YWGFMWXN>%]7\/6'PV@N]=DU.[NY/.M;F6#_CS5VMO+3:6.X)UZC..U/O\
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,J* $1-@I:** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>wst8klogosept122016.jpg
<TEXT>
begin 644 wst8klogosept122016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !5 -(# 2(  A$! Q$!_\0
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MZYQ?3OM2@I/Y-V_%HZ,%C/J?"%2VCJS<5\[7_!,^'"<"OZ#_ /@W_P#V7O\
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M/^NIK@?@=\)M3_:'^-WA7P78/)-JGC#5[?31*3E@9I 'E)_V5+.3Z U]A_\
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MV-'\.+6[<>&_AI;1JT"-\DVHW$:RRRL.Y2-XXQGI\^/O&O$O^",_PQ?XJ_\
M!3'X4V:INBTG4GUN8D9"K:0R3 G_ (&J#\:T_P#@MI\$?$/P<_X*-?$&[UJT
MN(['QE>_VYH]VRGRKVWD1 0C="8W#(PZC:.Q&>.NL/4XCI*=N:%)M>KE;\%?
M[SMP[Q%/ARK*%^6=1)^BC?\ %V^X^8?!6C6?B/QIH^G:CJ,.CZ?J%]!;76H3
M*6CL(GD57F8#J$4EB/\ 9K]9OVX?^""?@/1_V1=.U[]G[3O$_C;QF+FU\F6#
M68KR#6;5R1+,=Q6( #Y@8R!VP0:_(:O6/V:/VYOBS^Q_J"R_#SQQK.@VN_S)
M-.\P7&G3GOOMI T9)]0H/O7;G6 Q]:=.M@*W(X._*[\LO*5M?S.'(\PR^A"I
M1Q]'G4U;F5N:/I?3\CT'_AS=^T]G_DCGB3_P)L__ (]7W9X@_P""/_CWXV?\
M$OO@WX>\8>++?X:R_"FTUS6-8T[4-/-_*K37#RH"8Y@JA(5)P"W^L/TKNO\
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M(U7X-:W'X=\)2_VL8T-NEEIL]A>%A(APES)&Z1\9R6SD9'4UXC^SG^TMX/\
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M/]F_U-JI]O+C\P?]=C7X]_\ !5GQ%_PE'_!2+XT76[>$\3SVH/M"J0_^TZ^
MR;&_7>*<353O&G#D7RDK_C<_0,ZP7U'A;#TGI*I/G?S3M^%CQ%O%UZ?!:Z )
M"--6_.I&,?QS&)8@Q^B@@?[QKZ'_ ."07[+H_:P_;Z\$:)=6WVG0M"G/B+6
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
